AI English summary of an SEC filing — figures as filed
CVS Health CVSThe company said full-year 2024 total revenues rose to $372.8 billion, up 4.2% from the prior year, with GAAP diluted EPS of $3.66 and Adjusted EPS of $5.42. For full-year 2023, GAAP diluted EPS was $6.47 and Adjusted EPS was $8.74.
Key points
AI summaryThe company said full-year 2024 total revenues rose to $372.8 billion, up 4.2% from the prior year, with GAAP diluted EPS of $3.66 and Adjusted EPS of $5.42. For full-year 2023, GAAP diluted EPS was $6.47 and Adjusted EPS was $8.74.
CVS said the Health Care Benefits segment posted an adjusted operating loss of $439 million in Q4 2024, compared with adjusted operating income of $676 million a year earlier, and its MBR was 94.8%, versus 88.5% in the prior-year period. The company cited higher utilization, the unfavorable impact of Medicare Advantage star ratings, and higher acuity in Medicaid as factors behind the change.
The company said net cash provided by operating activities for full-year 2024 was $9,107 million (2023: $13,426 million). It presented full-year 2025 cash flow from operations guidance of approximately $6.5 billion.
CVS presented full-year 2025 guidance for GAAP diluted EPS of $4.58 to $4.83 and for Adjusted EPS of $5.75 to $6.00. The company cited amortization of intangible assets, acquisition-related integration costs, and office real estate optimization charges as items that account for the difference between the two measures.
Summary
AI-writtenAnalysis scope · Filing body and confirmed press-release exhibitWe analyzed the opening part of the filing body and confirmed exhibits, within a length limit. This is not a review of other exhibits, investor presentations or the full earnings call.
Full-year revenue $372.8 billion, adjusted EPS $5.42
The company said full-year 2024 total revenues rose to $372.8 billion, up 4.2% from the prior year, with GAAP diluted EPS of $3.66 and Adjusted EPS of $5.42. For full-year 2023, GAAP diluted EPS was $6.47 and Adjusted EPS was $8.74.
Source · Based on the filing body and exhibits
Q4 Health Care Benefits adjusted operating loss $439 million
CVS said the Health Care Benefits segment posted an adjusted operating loss of $439 million in Q4 2024, compared with adjusted operating income of $676 million a year earlier, and its MBR was 94.8%, versus 88.5% in the prior-year period. The company cited higher utilization, the unfavorable impact of Medicare Advantage star ratings, and higher acuity in Medicaid as factors behind the change.
Source · Based on the filing body and exhibits
Full-year operating cash flow $9,107 million, 2025 outlook about $6.5 billion
The company said net cash provided by operating activities for full-year 2024 was $9,107 million (2023: $13,426 million). It presented full-year 2025 cash flow from operations guidance of approximately $6.5 billion.
Source · Based on the filing body and exhibits
2025 full-year EPS guidance range
CVS presented full-year 2025 guidance for GAAP diluted EPS of $4.58 to $4.83 and for Adjusted EPS of $5.75 to $6.00. The company cited amortization of intangible assets, acquisition-related integration costs, and office real estate optimization charges as items that account for the difference between the two measures.
Source · Based on the filing body and exhibits
AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.
Original filing
The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.
Loading the filing text…